anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to an antioxidant, anti-inflammatory, anti-diabetic, whitening, anti-wrinkle, or gout suppressing composition comprising a Honggeum apple peel extract as an active ingredient. According to the present invention, the Honggeum (Malus pumila Mill.) apple peel extract, which is a newly-cultivated variety, has an antioxidant effect by inhibiting DPPH radical, ABTS radical, and TBARs and increasing PF, and exhibits an effect of inhibiting the inflammatory reaction by inhibiting hyaluronidase activity. In addition, the extract maintains the elastin molecule form by inhibiting elastase activity, exhibits an anti-wrinkle effect by inhibiting collagenase activity, and exhibits a skin whitening effect by inhibiting tyrosinase and suppressing melanin production. Further, the Honggeum apple peel extract prevents diabetes by inhibiting α-amylase and α-glucosidase enzyme activities and exhibits an effect of inhibiting gout (arthritis) by inhibiting the activity of xanthine oxidase enzyme. Therefore, according to the present invention, the Honggeum apple peel extract is expected to be useful as an antioxidant, anti-inflammatory, anti-diabetic, whitening, anti-wrinkle, or gout suppressing pharmaceutical composition, food composition, or cosmetic composition.
COVID-19 can present as a life-threatening disease characterised by respiratory failure and high circulating levels of inflammatory cytokines. Beta-glucans comprise a heterogeneous group of natural polysaccharides consisting of D-glucose monomers linked by a beta-glycosidic bond. They represent key structural elements of the cell wall and may serve as energy storage in bacteria, fungi including yeast, algae, and plants. In this triple-masked randomised trial, hospitalised patients requiring treatment with supplemental oxygen because of a laboratory-confirmed infection by SARS-CoV-2 will receive supplementation with 1-3 beta-glucans or placebo as part of their standard treatment. The primary endpoint of this trial is the intensity of clinical symptoms as detected by the Wisconsin Upper Respiratory Symptom Survey (WURSS).

Patients requiring mechanical ventilation at baseline will be excluded, as will those with cognitive impairment that precludes the use of clinical assessment scales, patients in which an order to limit therapeutic efforts has been issued, pregnant or breastfeeding women and those who decline to participate in this study. Secondary outcomes will include clinical deterioration requiring admission to an intensive care unit, requirement of high-flow nasal cannula or invasive mechanical ventilation and overall survival. Patients will be followed-up until hospital discharge or up to fifteen days after randomisation. Statistical analyses will be undertaken by a statistician unaware of treatment allocation under the intention-to-treat principle.
The invention relates to a recombinant adenovirus that has an oncolytic effect in a cancer cell. By modulating the level and type of splice isoforms of the E1B gene product, expressed from the E1B gene, the oncolytic activity of such viruses can be enhanced. The invention provides a recombinant adenovirus in which the proportion of the E1B-156R isoform is increased relative to wild-type levels. Such a recombinant adenovirus may selectivity replicate in cancer cells, thereby killing cancer cells, whilst sparing normal cells. Methods of forming the oncolytic adenovirus by modifying the sequence of the E1B gene to increase the level of the E1B-156R isoform are also claimed, along with methods of treating cancer using the aforementioned recombinant adenoviruses. The adenovirus with increased proportions of E1B-156R isoform may have a mutated splice recognition region, preferably at the E1B-93R splice site.
This group will receive AZD0530 (saracatinib) experimental oral drug , once daily, for a duration of 4 weeks. Dosage is 50mg per day.
ABSTRACT OF THE DISCLOSURE          A biodegradable composition for the controlled release of TGF-.beta. isdescribed. This composition is very useful for the delivery of TGF-.beta. in theregeneration of bone. The composition contains among other components, demineralized bone matrix and a degradable homopolymer or copolymer such as poly (lactic-co-glycolic acid). An implantable delivery system for TGF-.beta. release in a predictable and controlled manner with time is described in which an implantable support is formed or coated with this biodegradable composition, TGF-.beta. is stabilized in a composition containing an organic acid buffer, and to which additional components such as mannitol, human serum albumin, gelatin and/or a non-ionic detergent have been added.
Liposomal vaccine formulation and preparation thereof. The formulation relates to liposomes which contain encapsulated antigens in their interior or else associated with the membrane, with a phospholipid concentration of 25 mg/g relative to the final product. The antigens used can be viral antigens or antigen fractions of bacterial origin, such as endotoxins, adhesion factors, etc. The phospholipids used are mostly lecithins. Cholesterol and also a fat-soluble antioxidant can sometimes be added to the phospholipids. The preparation procedure involves adding the phospholipids to a suspension of the antigens, homogenizing the mixture by recirculation through a microfluidizer. The formulation is used for the preparation of liposomal vaccines for veterinary use.
The goal of this study is to test a complementary therapy intervention that will assist in improving quality of life (QOL) for women undergoing chemotherapy for late stage (III and IV) breast cancer within the context of conventional medical care. This longitudinal randomized clinical trial (RCT) will test a three-group design in which participants will continue to receive conventional care. Two groups of the study will involve a single-blinded four-week protocol: Group A will receive reflexology (a specialized foot therapy) from a certified reflexologist; Group B will receive placebo sessions from a research aide. The control group (Group C) will receive conventional medical care alone. The specific aims are: 1) to determine if women who receive either Groups (A or B) of an experimental protocol (reflexology or placebo) report significantly better QOL outcomes (total and subscales) at 7 weeks, 13 weeks, and longitudinally over time, relative to women receiving conventional care alone (Group C); 2) to determine if women who receive Group A of an experimental protocol (reflexology), report significantly better QOL outcomes (total and subscales) at 7 weeks, 13 weeks, and longitudinally over time, relative to women receiving Group B (placebo; 3) to determine if women who receive either Group A or B of an experimental protocol (reflexology or placebo), report significant differences on Intermediate Indicators (physical and emotional), at 7 weeks, 13 weeks, and longitudinally over time, relative to women receiving conventional care alone; and 4) to determine if the Intermediate Indicators mediate the group effect on the QOL outcomes (total and subscales) at 7 weeks. This has the potential of leading to an enhanced system of care through the integration of conventional and scientifically-based complementary therapies. It also focuses on advanced disease that is currently under investigation in terms of supportive care measures. Finally, this study utilizes an improved design over existing work. It is a RCT with adequate numbers to detect group differences, and could ultimately serve as a model for rigorous investigation of other complementary therapies.
This study aimed to evaluate the effect of Astragalus polysaccharides (PG2) on reducing chemotherapy-induced fatigue (CIF) and toxicity, thereby encouraging compliance to chemotherapy. This was a randomized, placebo-controlled, phase 2 study. Patients with stage II/III early breast cancer planning to undergo adjuvant anthracycline-based chemotherapy were randomly assigned to receive PG2 500 mg or placebo on days 1, 3, and 8 every 21 days. The fatigue global score (FGS) was assessed using the brief fatigue inventory (BFI)-Taiwan. The Breast Cancer-Specific Module of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 evaluated the health-related quality of life during the first four cycles of adjuvant chemotherapy. Overall, 66 eligible patients were equally randomized into the PG2 and placebo groups between March 01, 2018, and March 09, 2021. The mean change in the FGS and fatigue intensity did not significantly differ between both groups. However, the FGS and fatigue intensity were less aggravated in the first four cycles in the premenopausal-PG2 group than in the placebo group. Our study concluded PG2 combined with adjuvant chemotherapy can reduce CIF, insomnia, the negative effect on future perspectives, and improve global health status, especially for premenopausal patients with breast cancer. Trial registration number: NCT03314805 registered on 19/10/2017.
d-Pinitol (DP) is primarily found in Vigna sinensis, which has been shown to have hypoglycemic and protective effects on target organs. However, the mechanism of DP in treating diabetic sarcopenia (DS) is still unclear. To explore the underlying mechanism of DS and the protective targets of DP by high-throughput analysis of 16S rRNA gene, metabolome, and the proteome. Streptozotocin-induced SAMP8 mice were intragastrically administrated DP (150 mg/kg) for 8 weeks. Fecal 16S rRNA gene sequencing and gastrocnemius muscle metabolomic and proteomic analyses were completed to investigate the gut-muscle axis interactions. DP significantly alleviated the muscle atrophy in diabetic mice. Dysfunction of the gut microbiota was observed in the DS mice. DP significantly reduced the Parabacteroides, Akkermansia, and Enterobacteriaceae, while it increased Lachnospiraceae_NK4A136. Metabolome and proteome revealed that 261 metabolites and 626 proteins were significantly changed in the gastrocnemius muscle of diabetic mice. Among these, DP treatment restored 44 metabolites and 17 proteins to normal levels. Functional signaling pathways of DP-treated diabetic mice included nucleotide metabolism, β-alanine, histidine metabolism, ABC transporters, and the calcium signaling pathway. We systematically explored the molecular mechanism of DS and the protective effect of DP, providing new insights that may advance the treatment of sarcopenia.
Subjects have their insulin titrated via standard of care for 8 weeks. The Voice Assistant Device is limited to providing a daily reminder to take medication.
Biliary atresia (BA) is a disease characterized by intra- and extra-hepatic bile duct obstruction diagnosed in the neonatal period. If left untreated, this obstruction leads to biliary cirrhosis and early death. Although considered a rare disease (between 1/15,000 and 1/20000 births), it is the leading cause of neonatal cholestasis and liver transplantation in children. The reasons for this obstruction are still poorly known and might involve several factors (immune, infectious and possible toxin effect). The accumulating evidence point to genetic factors involved, yet they are not of the classic monogenic or Mendelian types. The purpose of this study is to collect the fluid samples, explanted liver tissue samples and dermal biopsy samples to enable investigators to perform the genetic and molecular analyses that might point to the gene(s) and cellular pathway involved in etiology of BA disease.
Systems, methods, and computer-readable media for analyzing and presenting healthcare information are described. Some embodiments may include a system configured to receive healthcare information relating to a patient and to generate a patient profile. The patient profile may include a physiological status as well as a physiological assessment and a treatment assessment based on the automatic and dynamic analysis of the healthcare information. The healthcare information and the patient profile may be updated and/or accessed in real-time or substantially real-time through client logic devices in communication with the system. In this manner, a healthcare professional may enter healthcare information for a patient that is readily accessible by other healthcare professionals through the system. The system may present navigation objects that include a plurality of navigation layers selectively displayed based on user input. In addition, information objects may be displayed to users based on user navigation selections.
Subjects receive 3 doses off WEE vaccine on Day 0, Day 7 ± 2 days, and Day 28-35 days. A booster will be administered on Day 180 ± 14 days and a sample collected for PRNT80 28-35 days later.
1. Technical Result Increase in efficiency of treatment, prevention of side-effects, providing the stable remission and complete recovery.          2. Essence Anticonvulsants are used for treatment of bronchial asthma, asthmatic status, asthmatic and allergic bronchitis, asthmatic syndrome, hyper reactivity of bronchi and broncho-spastic colitis and diseases proceeding with these syndromes, allergic and vasomotor rhinitis.            3. Field of Application Medicine, therapy.
BACKGROUND: This study aims to explore the effect of nutritional impact symptoms (NIS) on oral nutritional supplements (ONS) energy intake and use days among head and neck cancer (HNC) patients.
METHODS: A cross-sectional study was conducted among HNC patients in a hospital in western China between January 2019 and June 2020. The NIS was from the Patient-Generated Subjective Global Assessment (PG-SGA) scale. Mann-Whitney test was used to examine the differences between different kinds of NIS and ONS use days. Binary logistic regression was used to determine the effect of NIS on ONS energy intake.
RESULTS: The most prevalent four NIS were no appetite (35.3%), dysphagia (29.4%), vomiting (13.2%) and oral pain (12.5%), respectively. All patients in the study were malnutrition. Patients with xerostomia or oral pain had less ONS use days than those without these symptoms. Patients with vomiting (OR 0.09, 95% CI 0.02-0.50) or pain (OR 0.15, 95% CI 0.02-0.89) were less likely to have ONS energy intake ≥400 kcal/day than those without these symptoms after adjusting the confounding factors. In addition, one-point increase in total NIS score was associated with a lower proportion of ONS energy intake ≥400 kcal/day (OR 0.77, 95% CI 0.59-0.99).
CONCLUSION: Xerostomia, oral pain, vomiting and pain should be strengthened and intervened to improve ONS use and nutritional status among HNC patients with malnutrition.
BACKGROUND: Polycystic ovary syndrome (PCOS) is a complex multifactorial disorder with a substantial genetic component. However, the clinical manifestations of PCOS are heterogeneous with notable differences between lean and obese women, implying a different pathophysiology manifesting in differential body mass index (BMI). We performed a meta-analysis of genome-wide association study (GWAS) data from six well-characterised cohorts, using a case-control study design stratified by BMI, aiming to identify genetic variants associated with lean and overweight/obese PCOS subtypes.
RESULTS: The study comprised 254,588 women (5,937 cases and 248,651 controls) from individual studies performed in Australia, Estonia, Finland, the Netherlands and United States of America, and separated according to three BMI stratifications (lean, overweight and obese). Genome-wide association analyses were performed for each stratification within each cohort, with the data for each BMI group meta-analysed using METAL software. Almost half of the total study population (47%, n = 119,584) were of lean BMI (≤ 25 kg/m2). Two genome-wide significant loci were identified for lean PCOS, led by rs12000707 within DENND1A (P = 1.55 × 10-12) and rs2228260 within XBP1 (P = 3.68 × 10-8). One additional locus, LINC02905, was highlighted as significantly associated with lean PCOS through gene-based analyses (P = 1.76 × 10-6). There were no significant loci observed for the overweight or obese sub-strata when analysed separately, however, when these strata were combined, an association signal led by rs569675099 within DENND1A reached genome-wide significance (P = 3.22 × 10-9) and a gene-based association was identified with ERBB4 (P = 1.59 × 10-6). Nineteen of 28 signals identified in previous GWAS, were replicated with consistent allelic effect in the lean stratum. There were less replicated signals in the overweight and obese groups, and only 4 SNPs were replicated in each of the three BMI strata.
CONCLUSIONS: Genetic variation at the XBP1, LINC02905 and ERBB4 loci were associated with PCOS within unique BMI strata, while DENND1A demonstrated associations across multiple strata, providing evidence of both distinct and shared genetic features between lean and overweight/obese PCOS-affected women. This study demonstrated that PCOS-affected women with contrasting body weight are not only phenotypically distinct but also show variation in genetic architecture; lean PCOS women typically display elevated gonadotrophin ratios, lower insulin resistance, higher androgen levels, including adrenal androgens, and more favourable lipid profiles. Overall, these findings add to the growing body of evidence supporting a genetic basis for PCOS as well as differences in genetic patterns relevant to PCOS BMI-subtype.
The invention discloses a humanized anti-anthrax-toxin protective antigen neutralizing antibody Fab and applications thereof. A complementary decision area of a VL chain of the antibody has the following CDRs amino acid sequence: L-CDR1 shown in SEQ ID NO. 1, L-CDR2 shown in SEQ ID NO. 2, and L-CDR3 shown in SEQ ID NO. 3; and a complementary decision area of a VH chain of the antibody has the following CDRs amino acid sequence: H-CDR1 shown in SEQ ID NO. 8, H-CDR2 shown in SEQ ID NO. 9, and H-CDR3 shown in SEQ ID NO. 10. The antibody can be specifically combined with anthrax protective antigens (PA), so as to prevent the lethal factor hybrid LF from entering cells, thereby playing a protective role.
PURPOSE:To provide the titled preparation containing a substance having bitter taste as an active component, by using an alkali metal salt of 6-hydroxypurine nucleoside 5'-phosphate and a sweetener. CONSTITUTION:The objective medicinal drug preparation contains (A) an alkali metal salt of the compound of formula (X is H, NH2 or OH), (B) a sweetener (e.g. mannitol, saccharine, etc.) and (C) a medicinal drug component having strong bitter taste. The bitter taste of the drug component can be masked not only at the administration of the drug but also after the administration because of the residual sweet feeling left for about 5min after administration. The unagreeable after-taste of the drug can be eliminated in the above preparation. The amount of the compound of formula used as the masking agent is 3-10wt% based on the component having bitter taste and that of the sweetener is 0.1-15% of the bitter-taste component.
BACKGROUND: Patients with cancer present a higher risk of vaccine-preventable diseases. Recommended vaccinations are the most cost-effective measure to reduce the risk of transmission and related complications. Nevertheless, vaccination rates are inadequate. Oncologists have a central role in tailored vaccine communication to their patients. We present the results of a survey conducted by AIOM in 2022, focusing on the perception of the problem by oncologists.
MATERIALS AND METHODS: An anonymous 31-item online questionnaire was shared on 15 September 2022 on the AIOM website. The objectives of this survey were to examine the perception of Italian oncologists on vaccine-preventable diseases and the main available vaccines, their attitude towards recommending vaccines and the COVID-19 pandemic impact on their habits regarding vaccine-preventable diseases.
RESULTS: Between September 2022 and January 2023, 114 medical oncologists (5% of the members) completed the anonymous questionnaire. At the first oncological visit, only 30% of respondents usually propose a vaccination schedule to all their patient, 41% do not usually discuss vaccinations at the first visit and 29% recommend vaccines exclusively to specific categories of patients. For 56% of respondents, patients are more aware of the benefits of vaccines, whereas 36% reported that patients are worried of receiving too many vaccines.
CONCLUSION: This is the first survey conducted among Italian oncologists to better understand the perception and attitudes towards the vaccination. It highlights the urgent issues of educating and training oncologists in vaccine-preventable diseases and vaccine awareness and the need to build (or implement) a network of multidisciplinary collaborations.
The microkiller is a novel formula which is not currently available on the market, and refers to an antiseptic, antimicrobial solution for stimulating the tissue granulation and an early wound healing, without the side effects of the current products created for the same purpose than the microkiller. The four main components, currently available on the market, are: 1. - Isotonic saline solution at 0.9% 1000ml. 2. - Sodium hypochlorite or chloride (common name) at 5%. 3. - Sodium bicarbonate in powder, 50 grs, sterile. 4. - Chloramphenicol or chloramphenicol sol. From 15 ml, topic, at a concentration of 5 mg. per ml total 75 mgs. The microkiller is therefore a unique formula due to its components, formula and benefits.
PROBLEM TO BE SOLVED: To obtain a urinastatin-containing aqueous composition having excellent heat stability, and useful for treating respiratory diseases, allergic diseases or the like by compounding propylene glycol. SOLUTION: This composition contains propylene glycol (preferably, an official drug listed in the Japanese Pharmacopoeia; the amount of addition is 0.05-4 w/v%). The pH is preferably 5.0-7.0. The urinastatin(UTI) is purified by anion exchanger treatment or the like, and it has preferably a molecular weight of 67,000, an isoelectric point of 2-3 and a specific activity of about 1,000-4,000 unit/mg-protein. It is prepared by dissolving propylene glycol, a pH controller, a chelating agent and the like in purified water for injection, a UTI stock solution is added to the solution and, they are mixed. Subsequently, the pH of the solution is adjusted, and the volume is adjusted with purified water followed by sterilization treatment.
PCT No. PCT/JP95/00135 Sec. 371 Date Aug. 4, 1997 Sec. 102(e) Date Aug. 4, 1997 PCT Filed Feb. 2, 1995 PCT Pub. No. WO95/21163 PCT Pub. Date Aug. 10, 1995This invention relates to bicyclic amino group-substituted pyridonecarboxylic acid derivatives of the general formulaA-Priesters thereof and salts thereof, wherein: Pri is a pyridonecarboxylic acid residue, and A is a bicyclic amino group represented by the following formula and joined to the 7-position of the pyridonecarboxylic acid or a position equivalent to the 7-position thereof. wherein R1 and R2 may be the same or different and each represents a hydrogen atom, a lower alkyl group or an amino-protecting group; R3 and R4 may be the same or different and each represents a hydrogen atom, a halogen atom, a cyano group, a hydroxyl group, an oxo group, a lower alkoxy group or a lower alkyl group; and n is an integer of 0 or 1. The above-described pyridonecarboxylic acid derivatives, esters thereof and salts thereof are useful as antibacterial agents. This invention also relates to bicyclic amine compounds useful as direct intermediates for the synthesis of the above-described pyridonecarboxylic acid derivatives.
Patients will receive a lymphodepletion chemotherapy with fludarabine plus cyclophosphamide for three consecutive days(Day -5 to Day -3) before infusion of CD19-targeted chimeric antigen receptor T-cell (CD19 CAR-T). Patients will receive the CD19 CAR-T(also known as PL001) infusion on Day 0.